Piramal announced that it has signed an agreement to acquire worldwide rights to the molecular imaging research and development portfolio of Bayer through its newly created subsidiary – Piramal Imaging SA. The portfolio includes rights to florbetaben, which is in the final stages of its Phase III clinical trials. First Phase III results will be presented on April 25th2012 at the American Academy of Neurology’s 64th Annual Meeting in New Orleans.
Florbetaben is a PET tracer for the detection of beta-Amyloid plaque deposition in the brain, which is the pathological hallmark of disease in probable Alzheimer’s disease patients. Detection of beta-Amyloid depositions is expected to result in earlier diagnosis and more specific treatment of Alzheimer’s disease.
The Phase III trial showed that PET imaging with florbetaben reliably detects beta-Amyloid in the brain during life with great accuracy and thus shows value as a potential tool to aid in the diagnosis and assessment of Alzheimer’s disease. All study endpoints were met. The visual assessment procedure proposed for routine clinical practice demonstrated 100% sensitivity and 92% specificity with excellent inter-reader agreement (kappa = 0.88).
Commenting on the transaction, Mr. Ajay Piramal, Chairman Piramal Group, said, “This is the second acquisition of late stage assets after our acquisition of assets of BioSyntech in 2011, where we have recently received the European CE mark approval for an innovative bio-orthopaedic product for cartilage repair, BST-CarGel®, which enables the company to commercialize BST-CarGel® in all of the countries in the European Union. We plan to build a promising portfolio in the pharma space, including our newly acquired Molecular Imaging assets, which will help us create a global branded pharma business.”
As per the agreement, Piramal will have the intellectual property (including patents, trademarks and know-how), worldwide development, marketing and distribution rights of the lead compound florbetaben as well as other clinical and pre-clinical assets of Bayer’s molecular imaging business.
Piramal estimates that the new class of PET imaging agents for Alzheimer’s has a global market potential of up to $1.5 billionand is setting up a dedicated global commercial team for florbetaben. Core members of Bayer’s research and development team working on the portfolio will be joining Piramal Imaging, which will carry forward the development of florbetaben and take it through regulatory approval processes worldwide. Piramal is planning to file for regulatory approvals in 2012.
It is sad Mary Anne and very hard on family mebrmes not to mention costly if they need to go into a nursing home at some point. It’s been around a long time but maybe you heard it called dementia? I sure hope too they find a cure or better treatment for this horrific disease. With the huge population of baby boomers in our country it’s going to be very costly in the future taking care of all those that do get this disease.